*Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; and †The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):261-70. doi: 10.1097/QAI.0b013e3182a23e9a.
INTRODUCTION: The temporal relationship between incident tuberculosis (TB) and virological outcomes during antiretroviral therapy (ART) is poorly defined. This was studied in a cohort in Cape Town, South Africa. METHODS: Data regarding TB diagnoses, ART regimens, and 4-monthly updated viral load (VL) and CD4 count measurements were extracted from a prospectively maintained database. Rates of virological breakthrough (VL > 1000 copies/mL) and failure (VL > 1000 copies/mL on serial measurements) following initial VL suppression were calculated. Poisson models were used to calculate incidence rate ratios (IRRs) and identify risk factors for these virological outcomes. RESULTS: Incident TB was diagnosed in 391 (28.5%) of 1370 patients during a median of 5.2 years follow-up. Five hundred seventy-eight episodes of virological breakthrough and 231 episodes of virological failure occurred, giving rates of 10.0 episodes per 100 person-years and 4.0 episodes per 100 person-years, respectively. In multivariate analyses adjusted for baseline and time-updated risk factors, TB was an independent risk factor for adverse virological outcomes. These associations were strongly time dependent; the 6-month period following diagnosis of incident TB was associated with a substantially increased risk of virological breakthrough (IRR: 2.3, 95% confidence interval: 1.7 to 3.2) and failure (IRR: 2.6, 95% confidence interval: 1.6 to 4.3) compared with time without a TB diagnosis. Person-time preceding TB diagnosis or more than 6 months after a TB diagnosis was not associated with poor virological outcomes. CONCLUSIONS: Incident TB during ART was strongly associated with poor virological outcomes during the 6-month period following TB diagnosis. Although underlying mechanisms remain to be defined, patients with incident TB may benefit from virological monitoring and treatment adherence support.
引言:抗逆转录病毒治疗(ART)期间发生的结核病(TB)与病毒学结果之间的时间关系尚未明确。本研究在南非开普敦的一个队列中进行。
方法:从一个前瞻性维护的数据库中提取了有关 TB 诊断,ART 方案以及每 4 个月更新的病毒载量(VL)和 CD4 计数测量值的数据。计算了初始 VL 抑制后病毒学突破(VL > 1000 拷贝/mL)和失败(VL > 1000 拷贝/mL的连续测量)的发生率。使用泊松模型计算发病率比(IRR)并确定这些病毒学结果的危险因素。
结果:在中位 5.2 年的随访中,1370 例患者中有 391 例(28.5%)被诊断为活动性结核病。发生了 578 次病毒学突破和 231 次病毒学失败,分别为每 100 人年 10.0 次和每 100 人年 4.0 次。在调整了基线和时间更新的危险因素后,结核病是不良病毒学结果的独立危险因素。这些关联具有强烈的时间依赖性;与无 TB 诊断的时间相比,在诊断出活动性 TB 后的 6 个月内,病毒学突破(IRR:2.3,95%置信区间:1.7 至 3.2)和失败(IRR:2.6,95%置信区间:1.6 至 4.3)的风险大大增加。在 TB 诊断之前的个人时间或在 TB 诊断后超过 6 个月的时间与不良病毒学结果无关。
结论:ART 期间发生的活动性结核病与 TB 诊断后 6 个月内的不良病毒学结果密切相关。尽管潜在的机制尚待确定,但活动性结核病患者可能受益于病毒学监测和治疗依从性支持。
J Acquir Immune Defic Syndr. 2013-11-1
J Clin Tuberc Other Mycobact Dis. 2022-3-4
Int J Tuberc Lung Dis. 2015-12
PLoS Pathog. 2012-2-16
J Acquir Immune Defic Syndr. 2012-7-1